Franczyk, B. et al. MiRNA biomarkers in renal disease. Int. Urol. Nephrol. 54, 575–588 (2022).
Google Scholar
Bikbov, B. et al. Global, regional, and National burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet 395, 709–733 (2020).
Bağriaçik, E. & Dikmen, B. T. Self-management training in patients with chronic kidney disease undergoing hemodialysis: A systematic review. Semin Dial. 37, 91–100 (2024).
Google Scholar
Hazzan, A. D., Halinski, C., Agoritsas, S., Fishbane, S. & DeVita, M. V. Epidemiology and challenges to the management of advanced CKD. Adv. Chronic Kidney Dis. 23, 217–221 (2016).
Google Scholar
Mullins, L. J., Conway, B. R., Menzies, R. I., Denby, L. & Mullins, J. J. Renal disease pathophysiology and treatment: contributions from the rat. Dis. Model. Mech. 9, 1419–1433 (2016).
Google Scholar
Thurlow, J. S. et al. Global epidemiology of End-Stage kidney disease and disparities in kidney replacement therapy. Am. J. Nephrol. 52, 98–107 (2021).
Google Scholar
Connor, K. L. & Denby, L. MicroRNAs as non-invasive biomarkers of renal disease. Nephrol. Dial Transpl. 36, 428–429 (2021).
Schwarzenbach, H. Clinical relevance of circulating, Cell-Free and Exosomal MicroRNAs in plasma and serum of breast cancer patients. Oncol. Res. Treat. 40, 423–429 (2017).
Google Scholar
Nabawy, M. et al. Impact of some MiRNAs expression on induction of obesity related diseases. Egypt. J. Chem. 0–0. https://doi.org/10.21608/ejchem.2024.307399.10085 (2024).
Gouda, W. et al. Evaluation of the association of some circulating miRNA molecules in the metabolic syndrome. Qatar Med. J. (2024). (2024).
Nabawy, M. et al. Evaluation of some MicroRNAs dysregulation in obesity and obesity-related hypertension. Egypt. Pharm. J. 24, 199–206 (2025).
Sun, Q. et al. The feedback loop between miR-21, PDCD4 and AP-1 functions as a driving force for renal fibrogenesis. J Cell. Sci 131, (2018).
Fujii, R. et al. Circulating MicroRNAs (miR-126, miR-197, and miR-223) are associated with chronic kidney disease among elderly survivors of the great East Japan earthquake. BMC Nephrol. 20, 1–7 (2019).
Abdelsalam, L. et al. Expression of miRNAs-122, -192 and – 499 in end stage renal disease associated with acute myocardial infarction. Arch. Med. Sci. 15, 1247–1253 (2019).
Google Scholar
Chen, N. X. et al. Decreased MicroRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD). PLoS One. 8, e64558 (2013).
Google Scholar
Taïbi, F. et al. Possible involvement of MicroRNAs in vascular damage in experimental chronic kidney disease. Biochim. Biophys. Acta. 1842, 88–98 (2014).
Google Scholar
Rangrez, A. Y. et al. Inorganic phosphate accelerates the migration of vascular smooth muscle cells: evidence for the involvement of miR-223. PLoS One. 7, e47807 (2012).
Google Scholar
Motshwari, D. et al. MicroRNAs associated with chronic kidney disease in the general population and High-Risk Subgroups—A systematic review. Int. J. Mol. Sci. 24, 1792 (2023).
Google Scholar
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117–S314 (2024).
Kreutz, R. et al. European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur. J. Intern. Med. 126, 1–15 (2024). (2024).
American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in Diabetes-2024. Diabetes Care. 47, S20–S42 (2024).
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T)) method. Methods 25, 402–408 (2001).
Google Scholar
Yan, L. et al. MiR-21-5p links Epithelial-Mesenchymal transition phenotype with Stem-Like cell signatures via AKT signaling in keloid keratinocytes. Sci. Rep. 6, 28281 (2016).
Google Scholar
Kowara, M. et al. MicroRNA inhibiting atheroprotective proteins in patients with unstable angina comparing to chronic coronary syndrome. Int J. Mol. Sci 25, (2024).
Liu, F. et al. miR-192 prevents renal tubulointerstitial fibrosis in diabetic nephropathy by targeting Egr1. Eur. Rev. Med. Pharmacol. Sci. 22, 4252–4260 (2018).
Google Scholar
Xu, X. et al. MiR-18a and miR-17 are positively correlated with Circulating PD-1 + ICOS + follicular helper T cells after hepatitis B vaccination in a Chinese population. BMC Immunol. 19, 25 (2018).
Google Scholar
Mishra, P. et al. Descriptive statistics and normality tests for statistical data. Ann. Card Anaesth. 22, 67–72 (2019).
Google Scholar
YOUDEN, W. J. Index for rating diagnostic tests. Cancer 3, 32–35 (1950).
Google Scholar
Wang, H. et al. A review of long non-coding RNAs in ankylosing spondylitis: pathogenesis, clinical assessment, and therapeutic targets. Front Cell. Dev. Biol 12, (2024).
Al-Dmour, B. A., Al-Nawayseh, A. H. T., Al-Tarawneh, M. A. & Hani, Z. M. B. Antecedents of mental disorder among physically inactive employees study of Jordanian higher education institutions: mediated moderation of perceived threat of Covid-19 and psychological capital. Pakistan J. Life Soc. Sci 21, (2023).
Khan, A., Zahra, A., Mumtaz, S., Fatmi, M. Q. & Khan, M. J. Integrated In-silico analysis to study the role of MicroRNAs in the detection of chronic kidney diseases. Curr. Bioinform. 15, 144–154 (2020).
Ibrahim, R. A. & Saadoon, I. H. The role of miRNA- 126 in the development of end stage renal disease. Pakistan J. Life Soc. Sci. 22, 5905–5913 (2024).
Fourdinier, O. et al. Syndecan-1 and free indoxyl sulfate levels are associated with miR-126 in chronic kidney disease. Int. J. Mol. Sci. 22, 10549 (2021).
Google Scholar
Scullion, K. M. et al. Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease. iScience 24, 101937 (2021).
Google Scholar
Fujii, R. et al. Association between Circulating MicroRNAs and changes in kidney function: A five-year prospective study among Japanese adults without CKD. Clin. Chim. Acta. 521, 97–103 (2021).
Google Scholar
Carmona, A. et al. Inflammation, senescence and MicroRNAs in chronic kidney disease. Front Cell. Dev. Biol 8, (2020).
Nguyen, D. N. D., Chilian, W. M., Zain, S. M., Daud, M. F. & Pung, Y. F. MicroRNA regulation of vascular smooth muscle cells and its significance in cardiovascular diseases. Can. J. Physiol. Pharmacol. 99, 827–838 (2021).
Google Scholar
Nammian, P., Razban, V., Tabei, S. M. B. & Asadi-Yousefabad, S. L. MicroRNA-126: dual role in angiogenesis dependent diseases. Curr. Pharm. Des. 26, 4883–4893 (2020).
Google Scholar
Donderski, R. et al. Analysis of profibrogenic MicroRNAs (miRNAs) expression in urine and serum of chronic kidney disease (CKD) stage 1–4 patients and their relationship with proteinuria and kidney function. Int. Urol. Nephrol. 54, 937–947 (2022).
Google Scholar
Lange, T. et al. MiR-21 is up-regulated in urinary exosomes of chronic kidney disease patients and after glomerular injury. J. Cell. Mol. Med. 23, 4839–4843 (2019).
Google Scholar
Zang, J., Maxwell, A. P., Simpson, D. A. & McKay, G. J. Differential expression of urinary Exosomal MicroRNAs miR-21-5p and miR-30b-5p in individuals with diabetic kidney disease. Sci. Rep. 9, 10900 (2019).
Google Scholar
Khokhar, M. et al. Metformin mediates MicroRNA-21 regulated Circulating matrix metalloproteinase-9 in diabetic nephropathy: an in-silico and clinical study. Arch. Physiol. Biochem. 129, 1200–1210 (2023).
Google Scholar
Fouad, M., Salem, I., Elhefnawy, K., Raafat, N. & Faisal, A. MicroRNA-21 as an early marker of nephropathy in patients with type 1 diabetes. Indian J. Nephrol. 30, 21–25 (2020).
Google Scholar
Sayilar, E. I. Biomarker potential of urine miR-451 at different stages of diabetic nephropathy. J Diabetes Metab 07, (2016).
Gomez, I. G. et al. Anti–microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J. Clin. Invest. 125, 141–156 (2015).
Google Scholar
Metzinger-Le Meuth, V., Burtey, S., Maitrias, P., Massy, Z. A. & Metzinger, L. MicroRNAs in the pathophysiology of CKD-MBD: biomarkers and innovative drugs. Biochim. Biophys. Acta – Mol. Basis Dis. 1863, 337–345 (2017).
Google Scholar
Zhong, X. et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56, 663–674 (2013).
Google Scholar
Gomez, I. G., Nakagawa, N. & Duffield, J. S. MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis. Am. J. Physiol. Ren. Physiol. 310, F931–F944 (2016).
Zhou, Y. & Yang, J. Implications of MicroRNA in kidney metabolic disorders. ExRNA 2, 4 (2020).
Chau, B. N. et al. MicroRNA-21 promotes fibrosis of the kidney by Silencing metabolic pathways. Sci Transl Med 4, (2012).
He, F. et al. MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1. Diabetologia 57, 1726–1736 (2014).
Google Scholar
Petrica, L. et al. Interleukins and MiRNAs intervene in the early stages of diabetic kidney disease in type 2 diabetes mellitus patients. Biomark. Med. 13, 1577–1588 (2019).
Google Scholar
Jia, Y. et al. miRNAs in Urine Extracellular Vesicles as Predictors of Early-Stage Diabetic Nephropathy. J. Diabetes Res. 7932765 (2016). (2016).
Jenkins, R. H., Martin, J., Phillips, A. O., Bowen, T. & Fraser, D. J. Pleiotropy of microRNA-192 in the kidney. Biochem. Soc. Trans. 40, 762–767 (2012).
Google Scholar
Ma, X., Lu, C., Lv, C., Wu, C. & Wang, Q. The Expression of miR-192 and Its Significance in Diabetic Nephropathy Patients with Different Urine Albumin Creatinine Ratio. J. Diabetes Res. 6789402 (2016). (2016).
Milas, O. et al. Deregulated profiles of urinary MicroRNAs May explain podocyte injury and proximal tubule dysfunction in normoalbuminuric patients with type 2 diabetes mellitus. J. Investig Med. 66, 747–754 (2018).
Google Scholar
Al-Kafaji, G. & Al-Muhtaresh, H. A. Expression of microRNA–377 and microRNA–192 and their potential as blood–based biomarkers for early detection of type 2 diabetic nephropathy. Mol. Med. Rep. 18, 1171–1180 (2018).
Google Scholar
Chaiwangyen, W., Khantamat, O., Kangwan, N., Tipsuwan, W. & de Sousa, F. L. P. MicroRNA expression in response to environmental hazards: implications for health. Ecotoxicol. Environ. Saf. 300, 118420 (2025).
Google Scholar
Kamkar, L., Saberi, S., Totonchi, M. & Kavousi, K. Circulating MicroRNA panels for multi-cancer detection and gastric cancer screening: leveraging a network biology approach. BMC Med. Genomics. 18, 27 (2025).
Google Scholar
Wang, W. et al. Testing the accuracy of a three-miRNA panel for the detection of primary prostate cancer: a discovery and validation study. Future Oncol. 21, 2167–2176 (2025).
Google Scholar
Garmaa, G. et al. Panel MiRNAs are potential diagnostic markers for chronic kidney diseases: a systematic review and meta-analysis. BMC Nephrol. 25, 261 (2024).
Google Scholar
Matshazi, D. M. et al. Circulating levels of MicroRNAs associated with hypertension: A Cross-Sectional study in male and female South African participants. Front Genet 12, (2021).
Kondracki, B. et al. MicroRNA expression in patients with coronary artery disease and Hypertension—A systematic review. Int. J. Mol. Sci. 25, 6430 (2024).
Google Scholar
Fichtlscherer, S. et al. Circulating MicroRNAs in patients with coronary artery disease. Circ. Res. 107, 677–684 (2010).
Google Scholar
Tijsen, A. J., Pinto, Y. M. & Creemers, E. E. Circulating MicroRNAs as diagnostic biomarkers for cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 303, H1085–H1095 (2012).
Google Scholar
Guo, B. et al. MicroRNA-126: from biology to therapeutics. Biomed. Pharmacother. 185, 117953 (2025).
Google Scholar
Le, M. N. & Nguyen, T. A. Innovative MicroRNA quantification by qPCR. Mol. Ther. Nucleic Acids. 31, 628–630 (2023).
Google Scholar
Wang, Z. Y. et al. Advances in Point-of-Care Testing of microRNAs Based on Portable Instruments and Visual Detection. Biosensors 13, (2023).